Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Flu surges across U.S. as doctor visits reach highest level since 1997 - 210 Setting up camp Shelters That Offer Both Excellence and Isolation
- 3Could the Star of Bethlehem have actually been a comet?
- 4See the famous winged horse Pegasus fly in the autumn night sky
- 5Consumer outlook on UK economy falls to two-year low
- The Most Encouraging New companies to Look Out For
- Ice Spice's 'Big Guy' SpongeBob song is stuck in everyone's heads again — and TikTok is fueling it
- Am I a Summer, or is this a scam? What I learned from color analysis.
- Grasping the Elements of Medical caretaker Pay rates: Factors That Shape Your Pay
- Cyclone causes blackout, flight chaos in Brazil's Sao Paulo
- Apollo's impatient old-timers are rooting for NASA's return to the moon with Artemis II launch
- I’m a neuroscientist who taught rats to drive − their joy suggests how anticipating fun can enrich human life
- Ski Resorts Universally: A Colder time of year Wonderland Guide
- Investigating Inside Plan and Home Style: Change Your Residing Space
